**Figure S1:** PCA clustering of splicing inclusion level differences between treated and untreated PDX tumors.
**Figure S2:** Graph representing common transcription factors GFI1B (A) and TARDBP (B) that may induce concerted changes in the expression of pairs of splicing- and mitotic-related genes after a course of chemotherapy. A solid black lines connect a pair of co-expressed genes and red lines connect transcription factors with their target genes.
Figure S2: Graph representing common transcription factors GFI1B (A) and TARDBP (B) that may induce concerted changes in the expression of pairs of splicing-and mitotic-related genes after a course of chemotherapy. A solid black lines connect a pair of co-expressed genes and red lines connect transcription factors with their target genes.
Figure S3: Western blotting analysis of U87MG cells and their concentrated secretomes before and after treatment with 30 µM Cisplatin.
Figure S4: Pladienolide B increases the sensitivity of cancer cells to Cisplatin. (A) Viability assay of U87MG, Hela and MCF-7 cells that were pretreated with 2 nM of Pladienolide B (2 days) following treatment with different concentrations of Cisplatin (4 days). (B) FACS analysis of caspase 3/7 and SYTOX staining of SKOV3 cells treated with 0.5 nM Pladienolide B, 10 µM Cisplatin or both drugs together. (C) Cell cycle analysis of SKOV3 and HT29 cells treated for 3 days with 0.5 nM and 1 nM of Pladienolide B respectively. (D) FACS analysis for phospho ATM staining of Hela, A549 and HT29 cells that were cultivated with 1 nM Pladienolide B (2 days) and subsequently treated with indicated concentrations of Cisplatin (1 day).